Answers are grounded in this paper and cite their sources.
Methyl 2,6-dideoxy-4-O-methoxymethyl-α-L-erythro-hexopyranosid-3-ulose (1) reacted with potassium cyanide under equilibrating conditions to give methyl 3-C-cyano-2,6-dideoxy-4-O-methoxymethyl-α-L-arabino-hexopyranoside (11). The mesylate (12) derived from this cyanohydrin was converted by established procedures, although not without difficulty, into methyl 3-acetamido-2,3,6-trideoxy-4-O-methoxymethyl-3-C-methyl-α-L-ribo-hexopyranoside (17), which was then converted in a straightforward manner into methyl 3-acetamido-2,3,6-trideoxy-3-C-methyl-α-L-ribo-hexopyranoside (20). Inversion of the configuration at C-4 of the latter compound, by means of an oxidation–reduction sequence, yielded methyl 3-acetamido-2,3,6-trideoxy-3-C-methyl-α-L-xylo-hexopyranoside (22), a derivative of the novel branched-chain amino sugar found in antibiotic A35512B.
No takes yet. Share an insight, caveat, or question.
Brimacombe et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: